Evofem Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes women's sexual and reproductive health products. Its lead product candidate is Amphora that is in Phase 3 trial for contraception; and in Phase 2b/3 clinical trial for prevention of chlamydia and gonorrhea in women. The company is also developing vaginal gel product candidate for the treatment of recurrent bacterial vaginosis. Evofem Biosciences, Inc. is headquartered in San Diego, California.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:EVFM
Previous Symbol
CUSIPN/A
Phone858-550-1900
Debt
Debt-to-Equity RatioN/A
Current Ratio0.54
Quick Ratio0.54
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / Cash FlowN/A
Book Value$1.17 per share
Price / Book3.27
Profitability
EPS (Most Recent Fiscal Year)N/A
Net Income$-9,990,000.00
Net MarginsN/A
Return on Equity-201.32%
Return on Assets-257.34%
Miscellaneous
Employees23
Outstanding Shares25,870,000
Market Cap$92.35 million
OptionableNot Optionable
Evofem Biosciences (NASDAQ:EVFM) Frequently Asked Questions
What is Evofem Biosciences' stock symbol?
Evofem Biosciences trades on the NASDAQ under the ticker symbol "EVFM."
How were Evofem Biosciences' earnings last quarter?
Evofem Biosciences Inc (NASDAQ:EVFM) announced its earnings results on Wednesday, November, 7th. The biotechnology company reported ($0.71) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.37) by $0.34. View Evofem Biosciences' Earnings History.
When is Evofem Biosciences' next earnings date?
What price target have analysts set for EVFM?
5 brokerages have issued 12-month price objectives for Evofem Biosciences' shares. Their predictions range from $8.00 to $15.00. On average, they anticipate Evofem Biosciences' share price to reach $10.40 in the next year. This suggests a possible upside of 170.1% from the stock's current price. View Analyst Price Targets for Evofem Biosciences.
What is the consensus analysts' recommendation for Evofem Biosciences?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Evofem Biosciences in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Evofem Biosciences.
What are Wall Street analysts saying about Evofem Biosciences stock?
Here are some recent quotes from research analysts about Evofem Biosciences stock:
- 1. Cantor Fitzgerald analysts commented, ": We reiterate the Overweight rating and 12-month PT of $9 for EVFM stock. If successfully developed and commercialized, we believe Amphora will become an important product for sexually active women who elect not to practice contraception." (11/15/2018)
- 2. HC Wainwright analysts commented, "We utilize a discounted cash flow (DCF)-based approach, with a 15% discount rate and an effective tax rate of 30% applied to all future cash flows. Our probability of success for Amphora in contraception is 70%, which translates into a risk-adjusted net present value (rNPV) of $250M." (8/29/2018)
Has Evofem Biosciences been receiving favorable news coverage?
Media headlines about EVFM stock have been trending very positive this week, InfoTrie Sentiment reports. InfoTrie ranks the sentiment of press coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Evofem Biosciences earned a coverage optimism score of 4.0 on InfoTrie's scale. They also gave news stories about the biotechnology company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the company's share price in the near future.
Who are some of Evofem Biosciences' key competitors?
Some companies that are related to Evofem Biosciences include MediciNova (MNOV), Evolus (EOLS), resTORbio (TORC), Keryx Biopharmaceuticals (KERX), American Brivision (Holding) (ABVC), Stemline Therapeutics (STML), Aclaris Therapeutics (ACRS), Marker Therapeutics (MRKR), Verastem (VSTM), OptiNose (OPTN), Evelo Biosciences (EVLO), Minerva Neurosciences (NERV), Aratana Therapeutics (PETX), Albireo Pharma (ALBO) and Concert Pharmaceuticals (CNCE).
Who are Evofem Biosciences' key executives?
Evofem Biosciences' management team includes the folowing people:
- Ms. Saundra Pelletier, CEO & Director
- Mr. Justin J. File, Chief Financial Officer
- Dr. Kelly Culwell, Chief Medical Officer
- Mr. Alexander A. Fitzpatrick, Gen. Counsel & Sec. (Age 51)
- Mr. Russell Barrans, Chief Commercial Officer
Who are Evofem Biosciences' major shareholders?
Evofem Biosciences' stock is owned by many different of retail and institutional investors. Top institutional shareholders include Heartland Advisors Inc. (1.26%) and Vanguard Group Inc. (0.84%). Company insiders that own Evofem Biosciences stock include Alexander A Fitzpatrick, Kelly Culwell, Ltd Invesco, Russell Barrans, Saundra L Pelletier and Thomas G Lynch. View Institutional Ownership Trends for Evofem Biosciences.
Which institutional investors are buying Evofem Biosciences stock?
EVFM stock was bought by a variety of institutional investors in the last quarter, including Heartland Advisors Inc. and Vanguard Group Inc.. Company insiders that have bought Evofem Biosciences stock in the last two years include Alexander A Fitzpatrick, Kelly Culwell, Ltd Invesco, Russell Barrans, Saundra L Pelletier and Thomas G Lynch. View Insider Buying and Selling for Evofem Biosciences.
How do I buy shares of Evofem Biosciences?
Shares of EVFM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Evofem Biosciences' stock price today?
One share of EVFM stock can currently be purchased for approximately $3.85.
How big of a company is Evofem Biosciences?
Evofem Biosciences has a market capitalization of $92.35 million. Evofem Biosciences employs 23 workers across the globe.
What is Evofem Biosciences' official website?
How can I contact Evofem Biosciences?
Evofem Biosciences' mailing address is 12400 HIGH BLUFF DRIVE SUITE 600, SAN DIEGO CA, 92130. The biotechnology company can be reached via phone at 858-550-1900 or via email at [email protected]
MarketBeat Community Rating for Evofem Biosciences (NASDAQ EVFM)
MarketBeat's community ratings are surveys of what our community members think about Evofem Biosciences and other stocks. Vote "Outperform" if you believe EVFM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe EVFM will underperform the S&P 500 over the long term. You may vote once every thirty days.
